THE MEDICAL NEWS

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

Public health researchers have long examined how societal forces can shape health outcomes. Decades after redlining was outlawed, for example, researchers continue to document its lasting effects on life expectancy, chronic disease and access to healthcare resources in many communities.

SAFE Structure Designs, a Las Vegas-based defense engineering and manufacturing company led by President and CEO Johnny Buscema, is supporting 50 Legs as a donor and raising awareness of its work helping children and adults with limb loss access quality prosthetic legs.

Common ways of reporting perfluoroalkyl and polyfluoroalkyl substances (PFAS)-the man-made, so-called forever chemicals that pose environmental and health threats-could underestimate the concentration of PFAS in United States drinking water by as much as half, finds a study publishing October 23 in the Cell Press journal Cell Reports Sustainability.

Advances in breast cancer screening and treatment are helping doctors detect the disease earlier, tailor therapies to individual patients and, in some cases, spare women from unnecessary chemotherapy, radiation and surgery.